Summit Therapeutics Q3 2026 net loss narrows 10% year over year to $208.4 million

Bitget2026/11/04 22:39

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Summit Therapeutics’ third-quarter 2026 net loss narrowed 10% year over year to $208.4 million.
Research and development expenses rose 29% year over year to $169.1 million, driven by expanded ivonescimab studies and development costs.
Cash and investments totaled $629.8 million at September 30; AstraZeneca completed a $2 billion strategic equity investment on October 5.
The FDA’s decision on ivonescimab with chemotherapy for previously treated EGFR-mutated advanced lung cancer is targeted for November 14, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611041636BIZWIRE_USPR_____20261104_BW735455) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Summit Therapeutics Q3 2026 net loss narrows 10% year over year to $208.4 million

You may also like

Crypto prices